Xcout IntelAlzamend Neuro, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Alzamend Neuro, Inc. among biotech companies — ranked by similarity to what Alzamend Neuro, Inc. actually does, not by market-cap band.
Subscribe to see Alzamend Neuro, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc. at a glance
Alzamend Neuro, Inc. is a biotech company headquartered in Atlanta, United States. It is publicly listed (ALZN) with a market capitalisation of $4.2M. Xcout tracks 16 named people at Alzamend Neuro, Inc., including Stephan Jackman (Chief Executive Officer & Director).
Alzamend Neuro, Inc. leadership
- Stephan JackmanChief Executive Officer & Director
- William B. HorneChairman of Alzamend, Chief Executive Officer of Ault Alliance, Inc.
- David J. KatzoffChief Financial Officer
- Henry C. W. NisserExecutive Vice President, General Counsel and Director
- Kenneth S CragunSenior Vice President of Finance
- Milton Charles AultFounder & Vice Chairman
10 more named people on record for Alzamend Neuro, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Alzamend Neuro, Inc. competitors
Ranked by semantic similarity — how close each company is to Alzamend Neuro, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences (Therapeutics)
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Similar biotech company
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Similar biotech company
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
Biotechnology
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Similar biotech company
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Biotechnology
Intra-Cellular Therapies was a U.S. biopharmaceutical company focused on developing treatments for central nervous system disorders. Its principal product, CAPLYTA (lumateperone), is used to treat schizophrenia and depressive episodes associated with bipolar disorder in adults, serving patients and mental-healthcare providers.
Biotechnology
AtaiBeckley Inc. has its corporate headquarters located in New York, USA. The biopharmaceutical company is on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments.
Biotechnology
Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.
Biotechnology
Reunion Neuroscience is a clinical-stage biopharmaceutical company that develops innovative therapeutics for underserved mental health disorders. Its lead drug candidate, luvesilocin, is a proprietary 5-HT2A agonist designed to provide durable antidepressant effects for patients with mood and anxiety disorders.
Similar biotech company
Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic medicines for psychiatric and neurological disorders. Its programs have included BPL-003, an intranasal formulation of 5-MeO-DMT, intended for conditions such as treatment-resistant depression and alcohol use disorder.
Biotechnology
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Biotechnology
Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Alzamend Neuro, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Alzamend Neuro, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →